Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of tipifarnib and etoposide in
treating older patients with newly diagnosed acute myeloid leukemia. Tipifarnib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as etoposide, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Giving tipifarnib together
with etoposide may kill more cancer cells